Does TRICARE Cover Farxiga (Dapagliflozin)?

What TRICARE Formulary Tier Is Farxiga On?

Farxiga sits in the non-preferred brand tier of the TRICARE pharmacy formulary. That means beneficiaries pay the highest applicable cost-share at retail pharmacies, though the copay drops considerably when filling a 90-day supply through TRICARE's home-delivery pharmacy (Express Scripts). Generic dapagliflozin became available in the United States beginning in late 2025 following patent expiration on certain exclusivities; if a generic version has been added to the TRICARE formulary by the time of your fill, the tier classification and copay will differ. Confirm the current tier directly with Express Scripts at 1-877-363-1303 before submitting a PA request.

The TRICARE formulary is governed by the TRICARE Pharmacy Program regulations under 32 C.F.R. Part 199.21 [1]. Non-preferred brands require both a prior authorization and, for the diabetes indication, documented step therapy. Preferred alternatives in the SGLT2 inhibitor class that TRICARE typically lists ahead of Farxiga include empagliflozin (Jardiance), which also carries FDA approval for type 2 diabetes, heart failure, and CKD [2].

Dapagliflozin's FDA-approved indications span three distinct clinical areas: type 2 diabetes mellitus, heart failure (with both reduced and preserved ejection fraction as of the 2022 label update), and chronic kidney disease [3]. Each indication has a separate clinical basis, and TRICARE evaluates them independently during prior authorization review.

Why Farxiga Requires Prior Authorization on TRICARE

Prior authorization for Farxiga under TRICARE exists because the drug is a non-preferred brand in a class that includes preferred alternatives. PA is the mechanism TRICARE uses to verify that a specific clinical need justifies the higher-cost agent before the benefit pays.

For the type 2 diabetes indication, the PA request must typically document:

• A confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
• Current HbA1c value (most reviewers want a result within the past 90 days)
• Failure of or documented contraindication to metformin and at least one preferred SGLT2 inhibitor or other preferred agent
• The prescriber's attestation that the preferred alternative was tried for a clinically adequate period (generally 30 to 90 days) or is contraindicated

For the heart failure indication, the clinical bar shifts. DAPA-HF (N=4,744) demonstrated that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26 percent compared with placebo in patients with heart failure and reduced ejection fraction (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) [4]. Citing this trial directly in the PA letter, along with the prescriber's attestation that dapagliflozin is being used per the FDA label for HFrEF or HFpEF, strengthens approval odds considerably.

For the CKD indication, the DAPA-CKD trial (N=4,304) showed that dapagliflozin 10 mg reduced the composite of sustained decline in eGFR of at least 50 percent, end-stage kidney disease, or renal or cardiovascular death by 39 percent versus placebo (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [5]. That magnitude of benefit in a population with few other disease-modifying options is something reviewers and medical directors at Express Scripts recognize, which is why the CKD PA tends to move faster than the diabetes PA.

Step Therapy Requirements for Farxiga on TRICARE

Step therapy applies most consistently to the type 2 diabetes indication. TRICARE's approach mirrors commercial insurer practice: beneficiaries are generally required to try a preferred formulary agent in the same drug class first unless a documented contraindication or allergy exists.

For diabetes, the step often requires a trial of empagliflozin (Jardiance) at a therapeutic dose for 30 to 90 days. If the patient experienced a serious adverse event, had an inadequate glycemic response, or has a clinical reason the preferred agent cannot be used, the prescriber documents that in the PA request and the step is considered satisfied.

Step therapy does not apply in the same structured way for the heart failure or CKD indications, because TRICARE's formulary exception criteria recognize that the clinical trial data supporting dapagliflozin in CKD (specifically, the DAPA-CKD population included patients without diabetes, a population not covered by empagliflozin's label at the time of formulary review) [5][6]. The American Diabetes Association's 2024 Standards of Care in Diabetes recommend SGLT2 inhibitors for patients with type 2 diabetes and CKD with eGFR 20 to 45 mL/min/1.73 m², or with urine albumin-to-creatinine ratio above 200 mg/g, to reduce CKD progression [6]. Citing that guideline recommendation in a PA letter for a diabetic patient with CKD often satisfies TRICARE's clinical justification requirement.

The table below summarizes which step-therapy conditions apply by indication:

| Indication | Step Therapy Required | Typical Preferred Step Agent | |---|---|---| | Type 2 diabetes | Yes | Empagliflozin or metformin (if SGLT2 naive) | | Heart failure (HFrEF or HFpEF) | No (or waived with DAPA-HF citation) | N/A | | Chronic kidney disease | No (or waived with DAPA-CKD citation) | N/A |

How to Submit a TRICARE Prior Authorization for Farxiga

The PA request flows through Express Scripts, the pharmacy benefit manager for TRICARE. Prescribers can submit electronically through most major EHR systems via the CoverMyMeds platform, by fax to the Express Scripts PA department, or by calling the Express Scripts provider line.

A complete PA submission should include:

1. The patient's TRICARE ID and sponsor Social Security number or DoD ID
2. Diagnosis codes (ICD-10) matching the Farxiga FDA-approved indication being requested
3. Relevant lab values: HbA1c for diabetes, eGFR and UACR for CKD, echocardiogram findings (LVEF) for heart failure
4. Documentation of step therapy completion or contraindication
5. The specific Farxiga dose being requested (5 mg or 10 mg)
6. A clinical summary letter from the prescriber tying the patient's case to a named guideline or trial

TRICARE is required to render a PA decision within 14 days for a standard request and within 72 hours for an urgent request under the Defense Health Agency's guidelines [7]. In practice, straightforward HF or CKD submissions with complete documentation often receive a decision within 3 to 5 business days.

What to Do If TRICARE Denies Farxiga

A denial is not a final answer. TRICARE provides a three-level appeals process, and data from the Department of Defense health plan consistently shows that well-documented appeals succeed at a rate high enough to make the effort worthwhile.

Level 1: Reconsideration. Submit a written reconsideration request to Express Scripts within 90 days of the denial. Attach any missing clinical documentation, a letter of medical necessity from the prescriber, and direct references to DAPA-HF [4] or DAPA-CKD [5] if the indication is HF or CKD. The prescriber should explicitly state why the denied alternative is insufficient.

Level 2: TRICARE Formal Appeal. If the Level 1 reconsideration is denied, submit a formal appeal to the appropriate TRICARE regional contractor within 90 days of that denial. For active-duty family members and retirees in most regions, that contractor is Humana Military (East) or Health Net Federal Services (West). The formal appeal goes to a medical review officer who is a licensed clinician; a detailed physician-authored appeal letter citing FDA labeling [3] and named clinical trials carries significant weight at this stage.

Level 3: Independent Review / Hearing. If the formal appeal fails, beneficiaries can request an independent review or, for claims above a dollar threshold, request a hearing before an administrative judge under TRICARE's quasi-judicial review process [7]. Engaging a patient advocate or a benefits attorney is advisable at this stage.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes that access barriers for evidence-based medications "result in worse clinical outcomes for patients who cannot afford out-of-pocket costs," a principle that applies equally to cardiometabolic drugs like dapagliflozin [8]. Including this framing in a formal appeal letter reinforces that denial creates measurable clinical harm.

Can I Use the AstraZeneca Savings Card with TRICARE?

No. Federal anti-kickback statutes and the Other Health Insurance (OHI) coordination rules prohibit beneficiaries from using manufacturer copay assistance cards, coupons, or savings programs in conjunction with any federal health plan, including TRICARE, Medicare, Medicaid, or VA coverage [9]. Using a manufacturer card with federal coverage is not merely a policy violation, it can constitute fraudulent billing.

If Farxiga is denied by TRICARE and cost is a barrier, two legitimate paths exist. First, AstraZeneca's AZ&Me Prescription Savings Program offers free or reduced-cost Farxiga to patients who meet income criteria and who do not have coverage for the drug, including patients whose TRICARE claim was denied [10]. Second, a prescriber can sometimes obtain samples for bridge supply while an appeal is pending.

Farxiga for Weight Loss: Does TRICARE Cover That?

Dapagliflozin is not FDA-approved for weight loss as a standalone indication. Weight reduction is a secondary metabolic effect observed in clinical trials; in the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin produced a mean body weight reduction of approximately 1.5 kg compared to placebo at a median follow-up of 4.2 years [11]. That is a modest effect relative to GLP-1 receptor agonists like semaglutide, which produced 14.9 percent mean weight loss at 68 weeks in STEP-1 (N=1,961) [12].

TRICARE does not cover Farxiga for weight loss as a primary indication, and submitting a PA with weight loss listed as the sole justification will result in denial. The drug must be prescribed under one of its three FDA-approved indications and documented accordingly. If a patient has comorbid obesity and a covered Farxiga indication (type 2 diabetes, HF, or CKD), the PA is submitted under the covered diagnosis, and weight benefit is incidental.

Formulary Alternatives TRICARE May Prefer Over Farxiga

Understanding what TRICARE considers preferred helps anticipate step-therapy requirements and reinforces which clinical arguments to make when requesting Farxiga specifically.

Empagliflozin (Jardiance) holds FDA approval for type 2 diabetes, heart failure (HFrEF and HFpEF), and CKD as of its expanded label [2]. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25 percent versus placebo [13]. TRICARE typically prefers empagliflozin over dapagliflozin based on formulary contracting, not on a clinical superiority determination.

Canagliflozin (Invokana) appears on some TRICARE formulary tiers for the diabetes and CKD indications following the CREDENCE trial (N=4,401), which showed a 30 percent relative risk reduction in the primary kidney composite endpoint [14]. However, canagliflozin's higher rate of lower-limb amputation observed in CANVAS (HR 1.97 per 1,000 patient-years) [15] gives many prescribers clinical grounds to prefer dapagliflozin or empagliflozin, an argument that can be made explicitly in a PA letter.

How Long Does TRICARE Prior Authorization for Farxiga Last?

Most TRICARE prior authorizations for Farxiga are approved for 12 months. At the end of that period, the prescriber must resubmit with updated labs and a brief renewal attestation. For the CKD indication, if a patient's eGFR has declined below the threshold at which dapagliflozin is no longer recommended (eGFR <25 mL/min/1.73 m² based on the current FDA label for the diabetes indication, though the CKD label permits use down to eGFR 25 for its indication) [3], the prescriber should clarify which indication the renewal is supporting.

Renewal denials are less common than initial denials because the prescriber has 12 months of documented clinical benefit to reference. A brief paragraph in the renewal letter describing the patient's HbA1c trajectory, eGFR stability, or heart failure hospitalization record since starting dapagliflozin is a strong retention argument.

Cost Without TRICARE Coverage

If all appeals fail and TRICARE does not cover Farxiga, the retail list price runs approximately $620 per 30-day supply. GoodRx and similar discount programs may reduce that to roughly $550 to $590 depending on pharmacy and location, though these discounts cannot be layered with TRICARE [9].

AstraZeneca's AZ&Me program, for patients who qualify on income grounds and lack coverage, provides the drug at no cost or reduced cost [10]. Eligibility is generally limited to patients with household income at or below 600 percent of the federal poverty level.

The FDA first approved dapagliflozin in January 2014 for type 2 diabetes [3], and the cardiovascular outcome data from DECLARE-TIMI 58 [11] and the CKD data from DAPA-CKD [5] expanded its clinical profile substantially. At $620 per month, the cost-effectiveness calculus is most favorable for patients with HF or CKD, where the absolute risk reduction translates to a number-needed-to-treat low enough to satisfy pharmacoeconomic scrutiny.